Comparing Revenue Performance: ADMA Biologics, Inc. or Geron Corporation?

Revenue Showdown: ADMA Biologics vs. Geron Corporation

In the competitive landscape of biotechnology, revenue growth is a key indicator of success. Over the past decade, ADMA Biologics, Inc. has demonstrated a remarkable upward trajectory in revenue, growing from approximately $6 million in 2014 to an impressive $258 million by 2023. This represents a staggering increase of over 4,200%, highlighting ADMA's robust market presence and strategic advancements.

Conversely, Geron Corporation's revenue has seen a more volatile path, peaking at around $36 million in 2015 but declining significantly to just $237,000 in 2023. This decline underscores the challenges Geron faces in maintaining consistent revenue streams.

The data reveals a stark contrast in revenue performance between these two companies, with ADMA Biologics emerging as a clear leader in revenue growth. Investors and industry analysts will find these insights crucial for understanding the dynamics of the biotech sector.